"Very good - exactly what I wanted to hear :-)"
It actually couldn't be better -
> doubling C3 dosage =
no adverse safety + no dose limiting toxicity
> only 2 of 3 patients have reached evaluation but BOTH have stable disease
> reiterating that they WILL be presenting this 4C data at ASH
ann: data from final cohort of patients, page-13
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 24652453 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25089307 | 16 |
View Market Depth
| Last trade - 16.12pm 11/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable